Type 1 Diabetes TrialNet Pathway to Prevention Study
The Type 1 Diabetes TrialNet Pathway to Prevention Study offers screening to individuals at increased risk of type 1 diabetes, based upon having a family member with type 1 diabetes. Participants are tested for diabetes-related autoantibodies in the blood. These autoantibodies are proteins that can be used as a marker of the destruction of the insulin producing cells in the body that happens with type 1 diabetes. These autoantibodies may be detectable in the blood many years before the diagnosis of type 1 diabetes. Individuals who are found to have these autoantbodies during participation in this study are offered additional testing to help further determine their risk of developing type 1 diabetes. They also may be eligible to participate in other studies to try and delay or prevent the onset of type 1 diabetes.